AngioDynamics Statistics
Total Valuation
AngioDynamics has a market cap or net worth of $657.60 million. The enterprise value is $614.69 million.
| Market Cap | 657.60M |
| Enterprise Value | 614.69M |
Important Dates
The next estimated earnings date is Thursday, October 1, 2026, before market open.
| Earnings Date | Oct 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AngioDynamics has 41.33 million shares outstanding. The number of shares has increased by 1.65% in one year.
| Current Share Class | 41.33M |
| Shares Outstanding | 41.33M |
| Shares Change (YoY) | +1.65% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 10.36% |
| Owned by Institutions (%) | 79.61% |
| Float | 31.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.05 |
| Forward PS | 1.94 |
| PB Ratio | 3.87 |
| P/TBV Ratio | 6.33 |
| P/FCF Ratio | 1,290.42 |
| P/OCF Ratio | 212.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3,258.64, with an EV/FCF ratio of 1,205.95.
| EV / Earnings | n/a |
| EV / Sales | 1.91 |
| EV / EBITDA | 3,258.64 |
| EV / EBIT | n/a |
| EV / FCF | 1,205.95 |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.19 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 4.33 |
| Debt / FCF | 21.57 |
| Interest Coverage | -75.14 |
Financial Efficiency
Return on equity (ROE) is -20.77% and return on invested capital (ROIC) is -16.35%.
| Return on Equity (ROE) | -20.77% |
| Return on Assets (ROA) | -5.13% |
| Return on Invested Capital (ROIC) | -16.35% |
| Return on Capital Employed (ROCE) | -11.67% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | $506,604 |
| Profits Per Employee | -$58,136 |
| Employee Count | 632 |
| Asset Turnover | 1.17 |
| Inventory Turnover | 2.54 |
Taxes
In the past 12 months, AngioDynamics has paid $442,000 in taxes.
| Income Tax | 442,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.58% in the last 52 weeks. The beta is 0.32, so AngioDynamics's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +54.58% |
| 50-Day Moving Average | 14.47 |
| 200-Day Moving Average | 12.18 |
| Relative Strength Index (RSI) | 60.47 |
| Average Volume (20 Days) | 361,357 |
Short Selling Information
The latest short interest is 1.35 million, so 3.27% of the outstanding shares have been sold short.
| Short Interest | 1.35M |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 3.27% |
| Short % of Float | 4.26% |
| Short Ratio (days to cover) | 2.24 |
Income Statement
In the last 12 months, AngioDynamics had revenue of $320.17 million and -$36.74 million in losses. Loss per share was -$0.88.
| Revenue | 320.17M |
| Gross Profit | 174.89M |
| Operating Income | -22.47M |
| Pretax Income | -36.30M |
| Net Income | -36.74M |
| EBITDA | 188,000 |
| EBIT | -22.47M |
| Loss Per Share | -$0.88 |
Balance Sheet
The company has $53.86 million in cash and $10.96 million in debt, with a net cash position of $42.91 million or $1.04 per share.
| Cash & Cash Equivalents | 53.86M |
| Total Debt | 10.96M |
| Net Cash | 42.91M |
| Net Cash Per Share | $1.04 |
| Equity (Book Value) | 170.83M |
| Book Value Per Share | 4.10 |
| Working Capital | 88.68M |
Cash Flow
In the last 12 months, operating cash flow was $3.09 million and capital expenditures -$2.58 million, giving a free cash flow of $508,000.
| Operating Cash Flow | 3.09M |
| Capital Expenditures | -2.58M |
| Depreciation & Amortization | 22.66M |
| Net Borrowing | -375,000 |
| Free Cash Flow | 508,000 |
| FCF Per Share | $0.01 |
Margins
Gross margin is 54.62%, with operating and profit margins of -7.02% and -11.48%.
| Gross Margin | 54.62% |
| Operating Margin | -7.02% |
| Pretax Margin | -11.34% |
| Profit Margin | -11.48% |
| EBITDA Margin | 0.06% |
| EBIT Margin | -7.02% |
| FCF Margin | 0.16% |
Dividends & Yields
AngioDynamics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.65% |
| Shareholder Yield | -1.65% |
| Earnings Yield | -5.60% |
| FCF Yield | 0.08% |
Analyst Forecast
The average price target for AngioDynamics is $20.00, which is 25.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 25.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 5.44% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AngioDynamics has an Altman Z-Score of 1.67 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.67 |
| Piotroski F-Score | 5 |